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Abstract
Background: Asthma represents a significant clinical and economic burden to the US healthcare system. Along
with other clinical manifestations of the disease, elevated sputum and blood eosinophil levels are observed in
patients experiencing asthma exacerbations. The aim of this study was to evaluate the association between blood
eosinophil levels and asthma severity defined using Expert Panel Report 3 guidelines.
Methods: Patients with asthma diagnosis between 2004 and 2011 were extracted from the EMRClaims+ database
(eMAX Health, White Plains, NY) containing electronic medical records linked to insurance claims for over 675,000
patients. The date of first asthma diagnosis was defined as the ‘index date’. Patients were required to have at least 1
peripheral eosinophil test (elevated defined as ≥ 400 cells/μL) in the 12 month ‘assessment’ period following the
index date. We classified patients as those with mild asthma and moderate-to-severe asthma based on the pattern
of medication use, as recommended by the 2007 National Institutes of Health Expert Panel Report. Logistic regression
models were used to determine if patients with moderate-to-severe asthma had increased likelihood of an elevated
peripheral eosinophil count, after accounting for demographics and comorbidities.
Results: Among 1,144 patients with an asthma diagnosis, 60 % were classified as having moderate-to-severe asthma.
Twenty four percent of patients with moderate-to-severe asthma and 19 % of patients with mild asthma had an
elevated peripheral eosinophil count (p = 0.053). Logistic regression showed that moderate-to-severe asthma was
associated with 38 % increased odds of elevated eosinophil level (OR 1.38, 95 % CI: 1.02 to 1.86, p = 0.04).
Conclusion: Patients with moderate-severe asthma are significantly more likely to have an elevated peripheral
eosinophil count than patients with mild asthma.
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Background
The American Lung Association has reported that nearly
26 million people (84.8 per 1000 people) in the US suf-
fered from asthma in 2011, with children representing
27 % of them [1]. In terms of lifetime prevalence, asthma
was reported in almost 40 million people in the US in
2011 (129 per 1000 people) [1]. Asthma attacks were
recorded in 51 % of diagnosed patients, resulting in an
attack rate as high 43.1 per 1000 [1].
The first Expert Panel Report (EPR) Guidelines [2] for
asthma were established in 1991, focusing on patient
education, environmental control to avoid asthma triggers,
and assessment of asthma severity using lung function
measures. Throughout the years, the EPR has been revised
to reflect new research and novel treatment options;
EPR-3 (2007) is the latest update [2]. Disease severity is
central to EPR-3 guidance, with step-therapy recom-
mended to address an escalating need for more drugs,
at higher doses, with persistently uncontrolled disease.
Asthma exacerbations undoubtedly increase the clinical
and economic burden to patients and payers (emergency
treatment being costlier than planned therapy), and are as-
sociated with substantial morbidity and mortality [3, 4].
Much progress has been made over the years in identi-
fying external or environmental risk factors/triggers of
asthma attacks such as allergens, pollutants, irritants,
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etc. [2, 5, 6]. Recently the focus has shifted to better un-
derstanding different patient phenotypes to manage risk
and optimize outcomes. In order to prevent exacerbations
and progression to more severe disease, it is essential to
identify modifiable risk factors for asthma control spe-
cific to patient phenotypes. An emerging priority to
standardize biological markers in clinical research in
order to better evaluate patient outcomes with new and
available therapeutic modalities is evidenced by the for-
mation of an expert group by the National Institute of
Health (NIH) to classify key biological outcome measures
for federally sponsored asthma research. In the NIH
Asthma Outcomes report, different biomarkers are
grouped as “core”, “supplemental”, or “emerging”. Core
outcome biomarkers are required to be included in
NIH funded asthma clinical trials and observational
studies, whereas supplemental biomarkers are optional
[7]. According to the NIH Asthma Outcomes report,
multi-allergen screening of IgE against different aller-
gens is considered the only core biomarker [7]. Blood
eosinophils are a type of white blood cells that are a
part of immune responses and also responsible for in-
flammatory effects when triggered by allergens. Blood
eosinophil measurement is recommended as a supple-
mental biomarker by the NIH asthma report [7], suggest-
ing its optional use in NIH funded studies. Published
studies evaluating its association with asthma exacerbation
have reported significant association between blood eo-
sinophil elevation and asthma exacerbations [8–10]].
Blood eosinophil measurement is inexpensive and widely
collected as part of the Complete Blood Count (CBC) test.
This study aimed to correlate asthma severity (based
on EPR guideline step-therapy recommendations) and
eosinophil elevation. In the absence of patient reported
symptom classification, we explore the use of eosinophil
biomarkers to identify patients who remain at risk for
chronic exacerbation despite treatment.
Methods
Study design and data source
We conducted a retrospective data analysis of patients
with asthma diagnosis, extracted from the EMRClaims+
integrated health services database (eMAX Health, White
Plains NY) of patients located in the Midwest region of
the United States. The database includes administrative
insurance claims from approximately 675,000 lives linked
to an overlapping healthcare provider database of over 20
million electronic medical records data (EMR), including
laboratory values, and provider billing files.
Study population
The population was comprised of patients 12 years or
older, who had at least two encounters (separated by at
least 1 day) in the emergency room, outpatient or
inpatient setting with a primary or secondary diagnosis
of asthma (International Classification of Diseases-9-
Clinical Modification [ICD-9-CM] code 493.xx) between
January 2004 and July 2011 (“study period”). The date of
the first asthma diagnosis in the study period was recorded
as the index diagnosis date. The 12-month period follow-
ing the index diagnosis was considered the ‘assessment
period’. Patients were also required to have at least 1 eo-
sinophil test conducted during the assessment period. To
account for the masking effect of systemic steroid use on
eosinophil levels, patients only having eosinophil results
under 400 cells/μL and all those eosinophil tests conducted
while on systemic steroids (based on days of supply plus
14 days) were excluded. This approach minimizes mis-
classification of patients with lower eosinophil levels
due to systemic steroid use. Patients with confounding
diseases states of COPD, emphysema (ICD-9-CM codes:
491.xx-492.xx, 494.xx-496.xx), Churg Strauss syndrome/
Wegener’s granulomatosis (ICD-9-CM code: 446.4), eo-
sinophilia (ICD-9-CM code: 288.3), pulmonary fibrosis
(ICD-9-CM code: 516.3), allergic bronchopulmonary as-
pergillosis (ICD-9-CM code: 518.6), cystic and pulmonary
fibrosis (ICD-9-CM code: 277.x,515), and lung cancer
(ICD-9-CM code: 162.x) in the assessment period, were
excluded.
Study measures
Asthma severity was estimated using the medication use
information reported in outpatient and/or inpatient phar-
macy records during the assessment period using step-
treatment recommendations for mild, moderate or severe
disease by the EPR-3 criteria and adapted for use with
retrospective data based on clinical guidance from asthma
specialists (Table 1). Previous studies have defined ele-
vated eosinophil levels at ≥ 400 cells/μL and have found
very weak or no associations with severity at lower eosino-
phil cut-offs (≥200 cells/μL, ≥ 300 cells/μL) [8–10]. We
also classified patients based on available eosinophil test
results over the assessment period as “Elevated” if at least
one test result during assessment period that was ≥
400cells/μL, and ‘Normal’ if all available eosinophil test re-
sults were less than 400 cells/μL. Information on patient
demographics (age, race, gender) was extracted. Comor-
bidities were captured and controlled for using the Charl-
son Comorbidity Index (CCI) score which was calculated
for each patient. We also reported the top 5 comorbidities
observed by the CCI.
Data analyses
Descriptive statistics were used to compare baseline
characteristics between the different severity groups. Fre-
quency distribution of patients with elevated eosinophils
versus normal eosinophils were reported and cross tabu-
lated with asthma severity level. Chi-square tests were
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used to compare the proportion of patients with elevated
eosinophil between those that had mild and moderate-to-
severe asthma. Logistic regression was used to determine
the association between asthma severity (key factor) and
eosinophil elevation, adjusting for patient demographics
(age, race, gender), and comorbidity burden (the top co-
morbidities or CCI score, separately). To further assess
the appropriate cut-off level for elevated eosinophils, we
utilized cut-off levels adopted in other studies and con-
ducted sensitivity analyses by defining elevated eosinophils
as the cut off at ≥ 300 cells/μL and ≥ 140 cells/μL. All data
management and analyses were conducted using SAS En-
terprise Guide version 4.3 (SAS Institute Inc., Cary, NC).
Results
The study identified 2,164 patients with at least one eo-
sinophil test during the assessment period, of which
1,144 met our criteria for severity classification. Figure 1
provides a step-by-step breakdown of the study sample.
Forty percent of patients were classified as having mild
asthma and 60 % had moderate-to-severe asthma ac-
cording to study definitions.
There was a greater proportion of women compared
to men (Table 2), but the proportion was not significantly
different between the severity groups (p = 0.116). Mean
age of the overall sample was 47 years. Age distribution
was significantly different between the two severity groups
(P < 0.0001). Fifty-five percent of all asthmatics were in
the 36–64 year age group; however, almost 17.5 % of pa-
tients with mild asthma were children between the ages of
12–17 years compared to 5 % in patients with moderate-
to-severe asthma. Diabetes was a prominent comorbidity
recorded in 14 % of asthmatic patients but the proportions
of patients with diabetes were not significantly different
among between the two severity groups (p = 0.057).
Overall, 22 % of subjects had at least one elevated eosino-
phil level (Fig. 2). Unadjusted Chi-square analysis showed
that proportions of subjects with elevated eosinophils
were not significantly different between the two groups
(Moderate-to-Severe 24 %, Mild 19 %, p = 0.053). How-
ever, logistic regression showed a 38 % increase in the
odds (Odds ratio = 1.38, p = 0.040) of elevated eosinophils
for moderate-to-severe asthma compared to mild asthma
after adjusting for differences in demographic characteris-
tics and comorbidities (Fig. 3). Males were also more likely
to show elevated eosinophils.
Sensitivity analyses
Results of sensitivity analyses conducted for elevated eo-
sinophil level defined as ≥ 300 cells/μL showed that elevated
blood eosinophils was not associated with moderate-to-
severe asthma (OR: 1.07, 95 % CI: 0.83–1.38, p = 0.587.
Similarly, elevated eosinophils at ≥ 140 cells/μL also showed
no significant association with moderate-to-severe asthma
(OR: 0.957, 95 % CI: 0.747–1.226, p = 0.728).
Discussion
In this sample of commercially insured asthma patients
aged 12 years or older, we attempted to define asthma
severity by adopting recommended medications described
as step therapies, by EPR 3 guidelines. This study found a
clear association between asthma severity and peripheral
blood eosinophils, with moderate-to-severe asthma associ-
ated with increased likelihood of eosinophil elevation. The
finding is consistent with previous literature showing cor-
relation of sputum and blood eosinophil levels in asth-
matic patients. Jatakanon and colleagues [11] followed a
group of patients with asthma for a period of 8 weeks, and
baseline comparisons showed a significantly greater
sputum eosinophil count for the group that developed
exacerbations versus those that did not. The same study,
through step-wise forward regression, reported that in-
creased sputum eosinophil was associated with decreased
airway function in terms of decreased forced expiratory
volume (FEV) [11]. While the literature supports the asso-
ciation of blood eosinophil elevation with severity or func-
tional impairment generally, identification of a clinically
meaningful threshold eosinophil value seems far less clear.
Here we can only offer that our observed association be-
tween severity and eosinophil at ≥ 400 cell/ μL did not
hold for levels ≥ 300 cells/μL or ≥ 140 cells/μL. While this
does not provide evidence for the optimal threshold, it
does suggest that these lower cut-points may be of limited
value in assessing patient risk. The observed association
between blood eosinophil levels at ≥ 400 cell/ μL and
asthma severity supports the use of routine blood eo-
sinophil screening practices to identify the sub-segment
of patients with elevated eosinophil for more targeted
treatment plans.
Our findings have significant implications for the med-
ical management of asthma. Cost and resource use rises,
and quality of life decreases with asthmatic exacerbation
Table 1 Classification of patients by asthma severity adapted
from EPR-3 step-treatment recommendations
Severity EPR-3 Step-Treatment Recommendations
Mild • Low dose ICS, or
• Cromolyn, LTRA, Nedocromil, or Theophylline
Moderate-to-severe • Low-dose ICS + LABA OR Medium-dose
ICS OR Medium-dose ICS + LABA, or
• Low-dose ICS + either LTRA, Theophylline,
or Zileuton, or
• Medium-dose ICS + either LTRA,
Theophylline, or Zileuton
• High-dose ICS + LABA OR High-dose
ICS + LABA + oral corticosteroid,or
• High-dose ICS + LABA + _Omalizumab, or
High-dose ICS + LABA + oral corticosteroid
+ Omalizumab, or
• Omalizumab
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[12]. Emergency medical treatment for exacerbation in
asthma is more costly than a managed regimen [3];
moderate-to-severe asthmatics with exacerbations result
in 68–88 % greater annual all-cause healthcare expendi-
tures compared to those without exacerbation [3, 4]. In
light of these facts, proactive management of asthma
(especially severe asthma) has the potential to reduce
the frequency of and cost incurred by these patients.
The observed association of elevated blood eosinophil
with moderate-to-severe in this study supports the value,
among competing tests, of using blood eosinophil markers
to assess patient risk in order to promote more proactive
Fig. 1 Study sample
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management of this patient phenotype to reduce
exacerbations.
Limitations
Requiring more than one asthma-related encounter may
have resulted in over-representation of more severe pa-
tients; however, this criteria was implemented to reduce
the selection of cases where a single diagnosis was
assigned for suspected (but unconfirmed) asthma, a
common approach when using retrospective claims
data [13]. Asthma severity classification was based on
medication use as opposed to observed exacerbation or
impairment-based severity measures. While this classi-
fication technique may need to be validated against pa-
tient records or physician assessment, previous studies
have defined asthma severity based on medication use
Table 2 Demographic and comorbidity distribution of patients by severity level
Patient characteristics Asthma Severity p-value
Mild (n = 457) Moderate-to-severe (n = 687)
N (%) N (%)
Gender
Female 312 (68.27) 499 (72.63) 0.116
Race
White 222 (48.58) 340 (49.49) 0.821
Black 59 (12.91) 81 (11.79)
Hispanic 109 (23.85) 155 (22.56)
Other/Unknown 67 (14.66) 111 (16.16)
Age groups
12–17 years 80 (17.51) 36 (5.24) <0.0001
18–35 years 78 (17.07) 113 (16.45)
36–64 years 232 (50.77) 401 (58.37)
Greater than/equal to 65 years 67 (14.66) 137 (19.94)
Top 5 Comorbidities
Diabetes 53 (11.60) 107 (15.57) 0.057
Cancer/tumor 35 (7.66) 38 (5.33) 0.149
Congestive Heart Failure 23 (5.03) 45 (6.55) 0.288
Cerebrovascular disease 13 (2.84) 19 (2.77) 0.937
Renal disease 8 (1.75) 20 (2.91) 0.213
CCI Score Mean (SD) 1.49 (1.16) 1.52 (1.14) 0.701
Fig. 2 Distribution of Subjects by Asthma Severity and Eosinophil level
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(other than EPR-3 recommendations). Medication use
serves as the best available technique in case of claims and
administrative data. Lack of compliance with step-
treatment recommendations may have misclassified pa-
tient asthma- severity level. We believe our classification
approach is conservative, with potential misclassification
which under represents the moderate-to-severe group,
since poor compliance with step-treatment recommenda-
tions directionally is toward under-treatment of poorly
controlled patients (as opposed to over treatment of well
controlled patients). For some patients, eosinophil levels
may have been defined using only one eosinophil test re-
sult over the one-year assessment period, but severity was
defined based on medication use over the entire year; the
temporal bias/relationship of these two variables was not
assessed and should be considered as a limitation.
Conclusion
This study highlights the association between asthma se-
verity, defined by using EPR guidelines, and eosinophil
elevation. The probability of eosinophil elevation is in-
creased for patients with greater asthma severity. Blood
eosinophil level may represent an important characteristic
of disease severity as new therapeutic alternatives emerge
for this patient phenotype after exhausting less aggressive
medication regimes. Further research correlating blood
eosinophil level with risk-based severity and control
measures (such as asthma exacerbations leading to ER
visits and/or hospital admissions) is warranted to exter-
nally validate the presence of our observed association.
Evidence of the association between blood eosinophil
levels and asthma severity underscores the need for
treatment options designed for asthma patients with el-
evated eosinophil.
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